BioMed Research International

BioMed Research International / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 1250721 | 17 pages | https://doi.org/10.1155/2018/1250721

Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET) Syndrome: A Systematic Review

Academic Editor: Sheba Mohankumar
Received14 May 2018
Revised24 Sep 2018
Accepted28 Oct 2018
Published21 Nov 2018

Abstract

Background and Aim. ROHHADNET (rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor) syndrome is a rare disease with grave outcome. Although early recognition is essential, prompt diagnosis may be challenging due to its extreme rarity. This study aimed to systematically review its clinical manifestation and to identify genetic causes. Materials and Methods. We firstly conducted a systematic review on ROHHAD/NET. Electronic databases were searched using related terms. We secondly performed whole exome sequencing (WES) and examined copy number variation (CNV) in two patients to identify genetic causes. Results. In total, 46 eligible studies including 158 patients were included. There were 36 case reports available for individual patient data (IPD; 48 patients, 23 ROHHAD, and 25 ROHHADNET) and 10 case series available for aggregate patient data (APD; 110 patients, 71 ROHHAD, and 39 ROHHADNET). The median age at onset calculated from IPD was 4 years. Gender information was available in 100 patients (40 from IPD and 60 from APD) in which 65 females and 35 males were showing female preponderance. Earliest manifestation was rapid obesity, followed by hypothalamic symptoms. Most common types of neuroendocrine tumors were ganglioneuromas. Patients frequently had dysnatremia and hyperprolactinemia. Two patients were available for WES. Rare variants were identified in PIK3R3, SPTBN5, and PCF11 in one patient and SRMS, ZNF83, and KMT2B in another patient, respectively. However, there was no surviving variant shared by the two patients after filtering. Conclusions. This study systematically reviewed the phenotype of ROHHAD/NET aiming to help early recognition and reducing morbidity. The link of variants identified in the present WES requires further investigation.

1. Introduction

Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation (ROHHAD) syndrome is a rare disorder of respiratory failure and autonomic dysregulation with endocrine abnormalities [1]. The suffix -NET was later added to describe a subset of patients with ROHHAD who were found with neuroendocrine tumors (NET) as ROHHADNET [2].

ROHHAD or ROHHADNET may mimic genetic obesity syndromes and present with hypothalamic-pituitary dysfunctions which are not fully investigated [3]. Since the central respiratory control becomes progressively impaired in the patients, the outcome is often fatal and associated with cardiopulmonary arrest [4]. Prompt diagnosis based on early recognition is essential to provide timely respiratory support and to minimize morbidity and mortality. We thereby sought to systematically review the clinical manifestation, laboratory profiles, and treatment strategies of patients with ROHHAD/NET to help understanding and managing the disease. In addition, we performed whole exome sequencing (WES) in 2 patients with ROHHADNET in the attempt to identify the genetic causes.

2. Methods

2.1. Search Methods

We conducted a systematic review of the medical literature to identify all published cases of ROHHAD and/or -NET using the online databases of MEDLINE/PubMed, EMBASE, and Google Scholar, until July 7th, 2018. There were no language restrictions; non-English language articles were translated and included. The broad search query was designed to include “ROHHADNET” OR “ROHHAD”; OR “obesity” AND two of the following terms; “hypoventilation” OR “hypothalamic” OR “autonomic” OR “tumor” OR “neural crest tumor” OR “neuroendocrine tumor.” We reviewed the titles, abstracts, and full texts adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) individual patient data (IPD) guidelines (Figure 1; Supplementary Table S1) [5].

2.2. Eligibility Criteria

The basic criteria for consideration of the diagnosis of ROHHAD had been published by Ize-Ludlow et al. [6]. The criteria briefly included the following: (1) onset of rapid and extreme weight gain after an age of 1.5 years (typically 2–7 years) in a previously nonobese and seemingly normal child, (2) evidence of hypothalamic dysfunction, (3) alveolar hypoventilation, and (4) features of autonomic dysregulation. We collected published case reports and case series which contained data on clinical manifestations fulfilling the criteria of ROHHAD/NET. Due to the extreme paucity of data, congress abstracts were also included. All cases from the literature were included as applicable.

2.3. Exclusion Criteria

Duplicates, letters, commentaries, or replies were excluded. Original articles not containing patient data, such a review articles, were also excluded.

2.4. Selection of Studies

Two reviewers (J.M.L, and S.K.) working independently considered the potential eligibility of each abstract and title that resulted from the initial search. The full-text versions of the eligible studies were reviewed. Disagreements were harmonized by consensus and, if not possible, through arbitration by a third reviewer (J.I.S.).

2.5. Data Extraction

Data were extracted from all of the case reports and case series which were included in the systematic review. Demographic information included age, gender, and ethnicity. Clinical manifestation included presence of symptoms, such as hypothalamic dysfunction, hypoventilation, autonomic dysregulation, neuroendocrine tumors, and neurologic or other remarkable reports. Data regarding the laboratory findings, management strategy, and clinical outcomes were also examined.

2.6. DNA Preparation, Whole Exome Sequencing, Sequence Alignment, and Variant Calling

This study was approved by the institutional review board of the Severance Hospital, Yonsei University Health System (IRB No.2017-2991-001). There were two patients with ROHHADNET with available samples, Case 1 [7] and Case 2 [8] (Supplementary Table S2). After obtaining informed consent, whole blood (3 ml) was collected from the two individuals with ROHHADNET. Genomic DNA was extracted using RBC Lysis Solution, Cell Lysis Solution, and Protein Precipitation Solution (iNtRon Biotechnology, Inc). Whole exome capture was performed using the Agilent SureSelect V5 enrichment capture kit (Agilent Technologies). The enriched library was then sequenced using the HiSeq 2500 sequencing system (Illumina; 101-base paired-end sequencing). Image analysis and base calling were performed with the Pipeline software (Illumina) using default parameters. Sequence reads were mapped to the human reference genome assembly (GRCh37/hg19) using the CLC Genomic Workbench (version 9.0.1) software (QIAGEN). Mapping was performed using the “Map Reads to Reference” function of the CLC Genomic Workbench software with the following settings: mismatch cost, 2; insertion cost, 3; deletion cost, 3; length fraction, 0.5; similarity fraction, 0.9; and map to nonspecific reads, random. Nonspecific reads were ignored for count and coverage. All variants with a minimum coverage of 2 were called using the “Basic Variant Caller” function of the CLC Genomic Workbench and annotated.

2.7. Filtering and Evaluation of Variants

Whole exome sequencing was analyzed as previously described [9]. Briefly, variants with minor allele frequencies >1% in the single nucleotide polymorphism (dbSNP; version 138) or 1000 genomes (2504 individuals; phase 3 data) databases were excluded. In the second step, variants present in the homozygous or hemizygous state in 59 healthy individuals without ROHHAD syndrome (internal control WES data) were excluded. In step 3, synonymous variants and intronic variants not located within splice site regions were excluded. In step 4, a recessive inheritance pattern was assumed on the basis of the pedigree of affected individuals. Therefore, homozygous and biallelic compound heterozygous variants were retained, while single heterozygous variants were excluded from further evaluation. In Case 1 who was a male, hemizygous variants were also considered. De novo variants could not be evaluated because parental DNAs were not available. In the final step, the remaining variants were ranked based on conservation of the mutated amino acid residue across species and their probable impact on the function of the encoded protein. The remaining variants were confirmed in the original participant DNA samples by Sanger sequencing.

2.8. Copy Number Variant (CNV) Analysis

Analysis of CNV was performed using the paired-end WES data using the EXCAVATOR version 2.2 [10] and ExomeDepth version 1.1.10 tools [11] with default settings. The GRCh37/hg19 database was used as the reference assembly for calculation of GC content. The WES dataset of 11 internal control subjects was compared with that of the study participants. Copy number variations at specific target regions were estimated according to different CNV detection algorithms using the Agilent SureSelect V5 kit.

3. Results

In total, 321 articles were identified using electronic and manual search methods (Figure 1). After serially reviewing the titles, abstracts, and full texts, 46 eligible studies including 158 patients were included. Among them, there were 36 case reports available for individual patient data (IPD; 48 patients, 23 ROHHAD and 25 ROHHADNET) [3, 4, 7, 8, 1243]. The remaining ten studies were reporting patients in groups or cohorts and were therefore available for aggregate patient data (APD; 110 patients, 71 ROHHAD and 39 ROHHADNET) [6, 4450].

Data regarding gender were available in 100 patients (40 from IPD and 60 from APD). There were 65 females and 35 males showing female preponderance, and female to male ratio was 1.9 to 1. Aside from gender, most of clinical information was extracted from 36 case reports where IPD were available. Limited information was retrievable from 10 studies with APD. Detailed profiles of the studies and patients’ data are presented in Tables 1 and 2.


No.Patient No.Authors, yearAge/SexHeight (cm)/Weight (kg)/BMIPresenting symptomsRapid obesityHypothalamic dysfunctionHypoventilationAutonomic dysregulationBehavioral changesNeurologic findingsNeural crest tumorOther findingsNa (mmol/L)Prolactin (ng/mL)fT4 (ng/dL)TreatmentOutcome

11Park, 2010 [7]13/M161/70.6/28Pain on both thighs, gait disturbance, general weakness, cold body sensationNoYesYesYesNoSeizureGanglio-
neuroma
Rhabdo-
myolysis
19835.8 > 13.0.5 > 0.8Hydration,
IVIG
Alive

22Thaker,
2015 [12]
2/M163 (11 yr)/166.3 (11 yr)/62-NoNoNoYesYesNoNoNoNormal-1.04-Alive

33Gordon,
2015 [13]
4/F-/-/--NoDISleep apneaYesNoNoGanglio-
neuroblast
oma
No-Hyper-
prolactinemia
Hypo
-
thyroidism
CaffeineAlive

44Tellingen, 2015 [14]4/F-/-/-Rapid weight gain, growth retardationYesDIYesNoNoNoGanglio-
neuroma
No--Hypo
-
thyroidism
-Alive

55Grudnikoff,
2013 [15]
4/F-/-/-Weight gain, growth retardation, irritability, aggressionYesYesSleep apneaNoYesNoGanglio-
neuroma
No----Alive

66Patwari, 2011 [16]8/F150/45>80/36-YesPrecocious pubertySleep apneaPupil dilatationYesNoGanglio-
neuroblast
oma
Pneumonia,
scoliosis
15856-Artificial
ventilation
Alive

77Sartori, 2012 [17]4/M-/-/--YesPolyuria,
polydipsia
Sleep apneaYesYesNoNoNoNormalHyper-
prolactinemia
-IVIG,
artificial
ventilation
Alive

78Sartori,
2012 [17]
5/F-/-/--YesYesYesNoYesNoNoNo--Central
hypo-
thyroidism
-Alive

89Dhondt,
2013 [18]
3/F-/-/-Stagnation of neurodevelopment,
aggression,
hyperphagia
YesPrecocious pubertyYesYesYesYesNoNo---Artificial
ventilation
Alive

910Bougnères, 2008 [19]4/--/-22-YesYesYesYesMental retardation,
psychosis
NoGanglio-
neuroma
No156198.5-Alive

911Bougnères,
2008 [19]
3/--/-/40-YesYesSleep apneaYesMental retardationNoGanglio-
neuroma
No161399.8-Alive

912Bougnères,
2008 [19]
3/--/-/29-YesYesYesYesNoNoGanglio-
neuroma
No1501417.1-Alive

913Bougnères,
2008 [19]
3/--/-/35-YesYesSleep apneaYesNoNoGanglio-
neuroma
No1512216-Alive

914Bougnères,
2008 [19]
2/--/-/24-NoYesYesYesNoNoGanglio-
neuroma
No1453116-Alive

915Bougnères,
2008 [19]
2/--/-/44-NoYesYesYesNoNoGanglio-
neuroma
No1493412.4-Alive

1016Paz-Priel,
2011 [20]
5/F-/-/17 > 25-YesYesNoLeft exotropiaAggressive
behavior
NoGanglio-
neuroblast
oma
No-76.5NormalCyclophosphamide,
IVIG,
prednisone,
rituximab
Alive

1117Chandrakantan,
2012
[21]
5/F108/29/25-YesDIYesPupil dilatation,
pupil response decrease
NoNoGanglio-
neuroblast
oma
NoHyper NaHyper-
prolactinemia
-Artificial
ventilation,
tracheostomy
Alive

1118Chandrakantan,
2012
[21]
9/F137/54/29-YesDIYesChronic constipation,
neurogenic
bladder
NoDevelopmental
delay
NoNoHyper Na--Noninvasive
mask
Alive

1219Kocaay,
2014
[22]
13/F145/69/32 (10 yrs)Respiratory distress,
cyanosis
YesHypogonadism,
secondary amenorrhea,
precocious puberty
YesNoSocial withdrawalDrowsinessNoMegaloblastic
anemia,
acanthosis
nigricans,
Raynaud
phenomenon
1511.044 (10 yrs)0.88-Alive

1320Sumanasena,
2012 [23]
10/F-/35/-Progressive
respiratory difficulty,
edema
YesNoYesNoHallucinationDrowsinessGanglio-
neuroma
No167Normal--Alive

1421Abaci,
2013 [3]
3/M92 > 95.8 (9 mo)/20 > 25.7 (9 mo)/24>28Cyanosis,
recent onset dyspnea
YesPolyuria,
polydipsia
YesNoYesNoGanglione
Uroblasto
ma
No14344.70.75Cyclophosphamide,
IVIG,
dexamethasone,
rituximab
Alive

1522Atapattu,
2015
[24]
4/F-/-/-Excessive weight gain,
increase food seeking,
daytime somnolence
YesNoYesNoYesNoGanglione
uroma
Celiac
disease
---Hypertension
medication
Alive

1623Uçar,
2013
[8]
6/F-/-/-Blurring of consciousness,
recurrent fever
NoGH deficiencyYesNoNoYesHamartoma
tous
mass
with neural
elements
No15289-Desmopressin acetate,
ventilatory support
Alive

1724Sethi,
2014 [25]
5/F117/25 > 37/14>28Behavior outbursts,
poor school performance,
hyperphagia,
fever,
abdominal pain with rectal prolapse
YesYesNoBilateral tonic pupilsYesNoGanglione
uroblasto
ma
Metabolic
alkalosis
HypoNa-NormalEndotracheal intubation,
risperidone, benzodiazepines,
antipsychotic medications
Multiorgan failure,
death

1825Gallizia,
2012 [26]
3/F-/-/-Rapid weight gain,
polyuria,
sleep apnea
YesYesSleep apneaNoNoNoNoNo-Hyper-
prolactinemia
Normal-Alive

1826Gallizia,
2012
[26]
3/F-/-/-Rapid weight gain, fatigue,
polydipsia,
syncope episodes,
strabismus,
behavioral problems
YesYesNoStrabismusYesYesNoNo-Hyper-
prolactinemia
NormalMechanical
ventilation
Alive

1927Baronio,
2013
[27]
1/M-/-/-Severe obesity,
hyperreninemic hypertension
YesNoNoNoNoNoGanglione
uroblasto
ma
No--0.62Mechanical
ventilation,
brain
hypothermia,
steroid pulse
Alive

1928Baronio,
2013
[27]
2/F-/-/-Severe obesity,
hyperreninemic hypertension
YesGH deficiencyNoNoNoNoGanglione
uroblasto
ma
No-Hyper-
prolactinemia
0.17Mechanical
ventilation,
brain
hypothermia,
steroid pulse
Alive

2029Chow,
2014 [28]
15/M174/87/29Fever, headache,
vomiting,
weight gain
YesNoNoNoIrritability, lethargy, somnolenceNoNoNo150>123--Mechanical
ventilation,
IVIG,
methylprednisolone
Alive

2130Kot,
2012
[29]
9/Mshort stature/-/-Weight gain,
short stature,
hyperphagia,
hypodipsia,
thermal dysregulation,
excessive perspiration,
cold extremity,
livedo reticularis,
sleep apnea
YesHypodipsia, GH
deficiency
Sleep apneaYesNoNoNoNo161Hyper-prolactinemiaNormalGH replacementAlive

2231Cemeroglu,
2015 [30]
5/--/-/-Short stature,
obesity
YesDI, GH
deficiency
Sleep apneaYesFlat affectNoNoScoliosis157>153-0.9>0.5GH
replacement,
levothyroxine, desmopressin,
tonsillectomy,
adenoidectomy, CPAP
Alive

2332Chew,
2011 [31]
11/M-/35/26Fever, drowsiness,
shallow breathing
NoDI,
hypogonadism
Sleep apneaThermal dysregulation,
excessive sweating,
right divergent squint
0Seizure, developmental delayNoRespiratory
acidosis
192Hyper-prolactinemiaNormalAnti-epilepticsAlive

2433Petty,
2014 [32]
-/M-/-/-Weight gain,
enuresis,
sleep apnea, fever
YesNoYesTransient visual lossHallucinationNoNoThrombocy
topenia
---IVIG,
CPM,
rituximab
Alive

2534Maksoud,
2015
[33]
6/F119/38/27Abdominal
mass,
rapid onset obesity
YesPremature
thelarche, GH
deficiency
Sleep apneaUrinary incontinenceNoNoGanglione
uroma
Hepatitis C156-0.79-Alive

2635Sanklecha,
2016 [34]
2/F-/-/-Gait disturbance,
head jerky movement, nystagmus
YesDI, polyuria,
polydipsia
YesNoAggressivenessSeizureGanglione
uroblasto
ma
No189>115--Chemotherapy,
mechanical ventilation, tracheostomy,
nasal BIPAP,
rituximab, CPM
Cardiac arrest, sudden demise

2736Erensoy,
2016 [35]
8/F-/-/-Overweight,
recession, fatigue,
decreased school success
YesNoNoNoPoor school performance, MDD, ADHDNoNoNo---Fluoxetine,
methylphenidate
Alive

2837Al-Harbi,
2016 [36]
8/F126/45/28Progressive fatigue,
skin bluish discoloration,
fever
YesBreast enlargementShortness of breath, sleep apneaCold intolerance, excessive sweating,
altered pain sense
Slow mental function, poor school performance, sleepinessNoNoNo186Hyper-prolactinemiaNormalBIPAPAlive

2938Aljabban,
2016 [37]
4/F110/25/-Rapid weight gain,
excessive eating
Yespolyuria,
polydipsia
Sleep apneaCold extremity,
GI dysmotility
Mood alteration, anxiety, aggressiveness, recurrent fatigue, social withdrawal, sleepinessSeizureGanglio-
neuroma
NoNormal > 162-NormalAntipsychotics,
mechanical ventilation,
tracheostomy
Cardiac arrest, death

3039Bagheri,
2017 [4]
5/F120/40/-Cough,
cyanosis
YesCentral
hypothyroidism
Sleep apneaCold extremities, hyperhidrosis, constipationMood changeSeizureGanglio-
neuroblast
oma
Facial
plethora,
buffalo
neck
125Hyper-prolactinemia0.8Mechanical
ventilation,
tracheostomy
Alive

3140Galewicz-zielinska,
2012
[38]
9/--/-/--NoNoMixed sleep
apnea
NoYesNoNoTonsillar
hypertrophy
---BIPAPAlive

3241Jacobson,
2016 [39]
2/F-/-/40Hyperphagia,
weight gain (16.8 > 35.5 kg)
YesPartial
DI
Sleep apneaReduced pain perception,
strabismus
Social withdrawal, autismNoGanglio-
neuroblast
oma
Papular
rash
---Rituximab,
cyclophosphamide
Alive

3242Jacobson,
2016 [39]
3/M-/-/34Hyperphagia,
weight gain (18 kg for 3 mo)
YesYesSleep apneaexcessive sweating,
thermal dysregulation,
enuresis,
altered pain sense,
strabismus
Social withdrawalNoNoNo-Hyper-prolactinemia-Rituximab,
CPM
Alive

3343Lucas-Herald,
2012 [40]
1/F-/32 (3 yr)/22Hyperphagia,
food stealing
YesHyper-prolactinemia, GH deficiency, water imbalanceSleep apneaAltered pain perceptionNoNoNoRenal
failure
184--BIPAPAlive

3344Lucas-Herald,
2012 [40]
2/M-/33/29ObesityYesHyper-prolactinemia, failed GHMixed sleep apneaNoNoNoNoNo---BIPAPAlive

3445Ibanez-Mico,
2017 [41]
2/F-/-/-Obesity,
increased appetite
YesHyper-prolactinemia, Central hypothyroidism
Sleep apneaYesAggression, hyperactivity, impulsivityYesNoAltered
pain sense,
GI
dysmotility
1751661.05IVIG, steroids,
cyclophosphamide
Tracheostomy
Sudden death

3546Isasa,
2018 [42]
10/M136/66.5/34.92Seizures (hyponatremia)YesHyper-prolactinemia
Central hypothyroidism
Central hypoventilation
Thermal dysregulation
PolydipsiaAggressivenessYesNoNoHyper-/hypo----Alive

3647Siraz,
2018 [43]
7/F130/61/36.0obesityYesCentral hypothyroidism
DI, MDD, Central precocious puberty
GH deficiency
Hyper-prolactinemia
Secondary adrenal insufficiency
NoExcessive sweating
hypothermia
NoNoNoPulmonary hyper-tension
IQ 65
156330.7-Alive

3648Siraz,
2018 [43]
5/F101/31/30.4Obesity,
seizure
YesCentral hypothyroidism
Hyper-prolactinemia
Central
hypoventilation
YesAggressivenessYesNoCentral cyanosis
IQ of 3 years of age
164560.8TracheostomyAlive

ADHD, attention deficit hyperactivity disorder; BIPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CPM, cyclophosphamide; DM, diabetes mellitus; DI, diabetes insipidus; IVIG, intravenous immunoglobulin; IQ, intellectual quotient; GH, growth hormone; GI, gastrointestinal; OCD, obsessive-compulsive disorder; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Author, yearN° patients Age (yr)Sex (M/F)Rapid obesityHypothalamic dysfunction (N° patients)Hypoventilation (N° patients)Autonomic dysregulation (N° patients)Behavioral changes (N° patients)Neurologic symptoms (N° patients)Neuroendocrine tumors (N° patients)Other findings (N° patients)Na (mmol/L) (N° patients)Treatment (N° patients)Outcome (N° patients)

Gil, 2012 [44]5--YesYes(5), hypothyroidism(1), adrenal insufficiency(1),
precocious puberty(1)
Central apnea(2), transient obstructive apnea(2)Yes(5)Yes(2)NoGanglio-neuroma
(3)
No--Death(1)

Reppucci, 2014 [45]78.3
(4.7~10.1)
-YesNoYes(3), sleep apnea(5)NoNoNoYesNo--Alive

Barclay, 2016 [51]164.3-NoYes(16)Yes(16),Yes(16)NoNoYes(7)No-Artificial ventilation(16)Alive

Biancheri, 2013 [46]6-2/4YesHypothyroidism(5),
adrenal insufficiency(2),
precocious puberty(2)
Central apnea(4)NoYes(6)NoNoNoElectrolyte imbalance (6)-Alive

Napoli, 2014 [47]62~4-YesHypothyroidism(5),
adrenal insufficiency(3),
precocious puberty(2)
Central apnea(4)NoYes(6)NoNoNoElectrolyte imbalance (6)Non-invasive ventilationAlive

Napoli, 2014 [47]7--Yes(7)Hypothyroidism(6),
adrenal insufficiency(4),
precocious puberty(2)
Sleep apnea(7)NoYes(7)NoGanglio-neuroma
(3)
No--Alive

Ize-Ludlow, 2007 [6]15-6/9Yes(8)Hypothyroidism(5), adrenal insufficiency(4),
precocious puberty(2),
delayed puberty(2), amenorrhea(1), irregular menstruation(1),
premature adrenarche(2), hypogonadism(1),
SIADH(2), polydipsia(8), hypodipsia(4), polyuria(4)
Alveolar hypoventilation
(15). sleep apnea(8), cyanosis(4)
Ophthalmologic manifestations
(13), thermal dysregulation
(11), GI dysmotility(10), Altered pain perception(8),
altered sweating(8), cold extremity(6)
Depression(2),
flat effect(2), psychosis(2), behavioral outbursts(1),
bipolar disorder(1), emotional lability(1),
OCD(1), oppositional-defiant disorder(1),
Tourette’s syndrome(1), hallucination(1)
Syncope(1),
developmental delay(3), regression(3), seizure(5), hypotonia (4)
Yes(5)Scoliosis(3), type 2 DM(2), enuresis(4), asthma(3), hyper-somnolence(2), pneumonia(2)HyperNa (7), hypoNa (2)-Cardiac arrest(9)

Barclay, 2015 [48]35-14/21YesYes(35)Yes(35)Yes(35)NoNoYes(15)No-Artificial ventilation (35)Alive

Gueorguieva, 2011 [49]90~4-NoHypogonadism(4)Yes(9)Yes(9)Mental retardation(4)NoGanglio-neuroma
(6)
NoMean 150-Death (2)

Abel, 2010 [50]4-1/3YesNoAlveolar hypoventilationThermal dysregulation, cold extremity, altered pain perceptionEmotional lability, behavioral outburstNoNoNo--Alive

3.1. Individual Patient Data (IPD) from Case Reports

There were 48 patients in the 36 case reports, in which 100% were pediatric cases. The median age at the time of diagnosis was 4.0 years (range, 1-15). Twelve patients (12/40, 30 %) were boys, 28 (28/40, 70%) were girls, and no information could be retrieved in the 8 remainders. Female to male ratio from IPD was 2.3 to 1.

3.1.1. Clinical Presentation

The most common presentation of patients with ROHHAD/NET was rapid obesity and hypothalamic dysfunction found in 40 cases (83%) respectively, followed by hypoventilation reported in 36 cases (75%). Hypothalamic dysfunction presented in various forms of endocrine disorder, such as growth hormone deficiency (25%), diabetes insipidus (19%), and central precocious puberty (15%). Hypoventilation most commonly presented as obstructive sleep apnea (44%). For symptoms of autonomic dysregulation, ophthalmologic abnormality such as blurred vision was most commonly reported (25%), followed by altered pain perception (13%) and gastrointestinal dysmotility (13%). Excessive sweating was noted in 10% of the patients. Behavioral change was a common (60%) form of cognitive dysfunction, and the symptoms included mood changes, fatigue, social withdrawal, poor school performance, and intellectual disability. Other neurologic manifestations majorly included seizures, altered consciousness, sleep disturbance, and developmental delay. The clinical presentations of the patients are summarized in Table 3.


Clinical findingsTotal number of patients (n=48)
Number of patients ()

Rapid obesity 40 (83.3)
Hypoventilation36 (75.0)
 Obstructive sleep apnea21 (43.8%)
 Respiratory distress5 (10.4%)
 Cyanotic episodes4 (8.3%)
Hypothalamic dysfunction40 (83.3)
 Growth hormone deficiency13 (25.3%)
 Diabetes insipidus9 (18.8%)
 Polyuria/polydipsia8 (16.7%)
 Central precocious puberty7 (14.6%)
 Hypogonadotropic hypogonadism2 (4.2%)
 Premature thelarche2 (4.2%)
Autonomic dysregulation32 (66.7)
 Ophthalmologic abnormality12 (25.0%)
 Altered perception of pain6 (12.5%)
 Gastrointestinal dysmotility6 (12.5%)
 Cold extremity4 (8.3%)
 Neurogenic bladder4 (8.3%)
 Excessive sweating5 (10.4%)
 Thermal dysregulation3 (6.3%)
 Syncope1 (2.1%)
 Urinary incontinence1 (2.1%)
Behavioral disorders29 (60.4)
 Irritability & aggression10 (20.8%)
 Fatigue4 (8.3%)
 Social withdrawal4 (8.3%)
 Poor school performance3 (6.3%)
 Intellectual disability2 (4.2%)
  Mood change2 (4.2%)
 Flat affect2 (4.2%)
 Hallucination2 (4.2%)
 Major depressive disorder1(2.1%)
 Attention deficit disorder1(2.1%)
 Psychosis1(2.1%)
Neurologic abnormality16 (33.3)
 Seizure7 (14.6%)
 Blurring of consciousness4 (8.3%)
 Sleep disturbance3 (6.3%)
 Developmental delay3 (6.3%)
 Gait disturbance2 (4.2%)
 Nystagmus1 (2.1%)
 General weakness1 (2.1%)
Other findings
 Fever6 (12.5%)
 Papular rash3 (6.3%)
 Enuresis2 (4.2%)
 Scoliosis2 (4.2%)
 Rhabdomyolysis1 (2.1%)
 Pneumonia1 (2.1%)
 Headache1 (2.1%)
 Megaloblastic anemia1 (2.1%)
 Thrombocytopenia1 (2.1%)
 Acanthosis nigricans1 (2.1%)
 Raynaud phenomenon1 (2.1%)
 Celiac disease1 (2.1%)
 Metabolic alkalosis1 (2.1%)
 Hepatitis C1 (2.1%)
 Buffalo neck1 (2.1%)
 Tonsillar hypertrophy1 (2.1%)
 Abdominal mass1 (2.1%)
 Renal failure1 (2.1%)
 Edema1 (2.1%)
 Pulmonary hypertension1 (2.1%)
 Cough1 (2.1%)

3.1.2. Laboratory Findings

In 13 patients who had available datasets, all had hypoxemia at initial presentation and hypercapnia was also dominant (14/15, 93%; Table 4). Dysnatremia was accompanied in most of the patients (30/31, 97%): 25 hypernatremia and 5 hyponatremias. Hyperprolactinemia (27/28, 96%), decreased IGF-1 level (12/16, 75%), and hypothyroidism (18/30, 60%) were also common.


Laboratory findingsTotal number of patients (n=48)
Number of patients ()

ABGA
 Hypoxemia13/13(100%)
 Hypercapnia14/15 (93.3%)
 Normal0/15 (0%)
 No information34/48 (70.8%)
Dysnatremia
 Hypernatremia25/31 (80.6%)
 Hyponatremia5/31 (16.1%)
 Normal2/31 (6.5%)
 No information17/48(35.4%)
Prolactin
 Hyperprolactinemia27/28 (96.4%)
 Normal1/28 (3.6%)
 No information19/48 (39.6%)
Thyroid dysfunction
 Hypothyroidism18/30 (60.0%)
 Normal12/30 (40.0%)
 No information17/48 (35.4%)
IGF-1 level
 Low12/16 (75.0%)
 Normal4/16 (25.0%)
 No information31/48 (64.6%)

ABGA: Arterial blood gas analysis, IGF-1: Insulin-like growth factor-1.
Hypoxemia is defined in terms of reduced partial pressure of oxygen below 80 mmHg or decreased oxygen saturation less than 90%.
Hypercapnia is defined in terms of elevated carbon dioxide above 45 mmHg.
3.1.3. Treatment Strategies and Survival

At the time of diagnosis, high proportion of patients (21/48, 44%) required respiratory support: mechanical ventilation in 20 (42%) cases and tracheostomy in 6 (13%) cases (Table 5). Six of the 44 (14%) patients were treated with steroids, while other immunosuppressive measures including rituximab and/or cyclophosphamide were administered in 7 cases (7/48, 14%). There were 4 deaths (3 sudden cardiac arrests and 1 multiorgan failure after sepsis) out of the 48 cases (Table 1).


TreatmentTotal number of patients (n = 48)
Number of patients ()

Respiratory support21 (43.8)
 Mechanical ventilation20 (41.7%)
 BIPAP7 (14.6%)
 CPAP1 (2.1%)
 Noninvasive mask1 (2.1%)
 Tracheostomy6 (12.5%)
Steroids7 (14.6)
 Methylprednisolone2 (4.2%)
 Steroid pulse therapy2 (4.2%)
 Prednisolone2 (2.1%)
 Dexamethasone1 (2.1%)
Fluid resuscitation4 (8.3)
Intravenous immunoglobulins7 (14.6)
Immunosuppressive agents7 (14.6)
 Rituximab5 (10.4%)
 Cyclophosphamide6 (12.5%)
Other agents
 Antipsychotics3 (6.3%)
 Desmopressin acetate2 (4.2%)
 GH replacement2 (4.2%)
 Anti-epileptics2 (4.2%)
 Levothyroxine4 (8.3%)
 Caffeine1 (2.1%)
 Hypertensive medication1 (2.1%)
Procedure2 (4.2)
 Brain hypothermia1 (2.1%)
 Tonsillectomy1 (2.1%)

BIPAP: bilevel positive airway pressure; CPAP: Continuous Positive Airway Pressure; GH: growth hormone.
3.1.4. Tumor Presentation

Out of 48 patients, twenty-five had neuroendocrine tumors (52.1%). The features of the tumors are described in Table 6. The most common type was ganglioneuromas: 15 ganglioneuromas (60%), 9 ganglioneuroblastomas (36%), and 1 hamartoma with neural tissue (2%). Although the lesions usually presented as intra-abdominal mass, 2 cases with mediastinal masses were reported.


Author, year [ref] Type/histologyLocation/sizeAssociated symptoms/signsTreatment

Park, 2010 [7]GanglioneuromaRight adrenalN/AIVIG

Gordon, 2015 [13]GanglioneuroblastomaLeft adrenalN/AN/A

Tellingen, 2015 [14]GanglioneuromaN/AN/AN/A

Grudnikoff, 2013 [15]GanglioneuromaN/AN/Aresection

Patwari, 2011 [16]GanglioneuroblastomaRight paraspinalN/AN/A

Bougnères, 2008 [19]Ganglioneuroma (6 patients)1 mediastinal
2 right adrenal
3 left adrenal
N/AN/A

Paz-Priel, 2011 [20]GanglioneuroblastomaRetroperitoneal massOpsoclonus- myoclonus-ataxia syndromeresection, cyclophosphamide, IVIG

Chandrakantan, 2012 [21]GanglioneuroblastomaLeft adrenalN/Aresection

Sumanasena, 2012 [23]GanglioneuromaLeft adrenalN/Aresection

Abaci, 2013 [3]Ganglioneuroma/ intermixed type with favorable histologyRetroperitoneal mass
(6.5 × 3.5 × 2.0 cm)
N/AResection, cyclophosphamide, IVIG, dexamethasone

Atapattu, 2015 [24]GanglioneuromaRight adrenalN/Aresection

Ucar, 2013 [8]Hamartomatous mass with neural elements of benign natureParahilar mass (2.5 cm)N/AResection

Sethi, 2014 [25]GanglioneuroblastomaRight adrenal mass
(4.0 × 3.0 × 4.0 cm)
N/AN/A

Baronio, 2013 [27]Ganglioneuroblastoma intermixedN/AHypertension, Cushing syndromeResection

Maksoud, 2015 [33]GanglioneuromaParavertebral mass (8.0 × 3.5cm) compressing the right ureterRight hydroureteronephrosisResection

Sanklecha, 2016 [34]GanglioneuroblastomaParavertebral massGait disturbanceResection, chemotherapy (not specified)

Aljabban, 2016 [37]GanglioneuromaPosterior mediastinal mass
(10 × 10 cm)
N/Aresection

Bagheri, 2017 [4]GanglioneuroblastomaMediastinal mass (1.5 cm)N/AN/A

Jacobson, 2016 [39]GanglioneuromaN/AN/Aresection

IVIG, intravenous immunoglobulin; N/A, not available for information.
3.2. Aggregate Patient Data (APD)

The 10 studies with APD included 110 patients (Figure 1; Table 2). Although limited data were available regarding age, all of the reported were pediatric cases. Sixty patients were available for gender information: 23 males (38%) and 37 females (62%). Female predilection was consistently noted. Rapid-onset obesity was observed in 65% (71/110) of the patients. Hypoventilation was reported in 51/110 (46%) patients, 63% of them (32/51) presented with sleep apnea, supporting the findings from IPD. Autonomic dysfunction was reported in 80/106 (75%) patients and behavioral changes were observed in 40/110 (36%). There were 46/110 (42%) patients who had neuroendocrine tumors and ganglioneuroma was the most common type as in IPD (12/46; the remaining 34 were not available for histology). In line with the IPD results, dysnatremia was the most commonly observed electrolyte imbalance (21/27, 78%). Information regarding treatment strategies was available in 51 patients and 100% of them eventually received artificial ventilation. There were 12 deaths (9 sudden cardiac arrests and 2 not available for cause of death) out of the 110 patients. The frequencies and characteristics of clinical manifestation generally conformed to those from IPD.

3.3. Next Generation Sequencing

We described previously reported human candidate genes [6, 12, 5154] for ROHHAD/NET in Table 7. None of these, however, have been identified in the patient cases to date. In our study, there were two ROHHADNET patients with available samples for whole exome sequencing: Case 1, a 15-year-old Korean boy [7]; and Case 2, a 5-year-old Turkish girl [8]. Details with regard to these two patients are briefed in Supplementary Table S2. Currently, there is no known genetic cause for ROHHAD or ROHHADNET [55]. To identify genetic variants related to ROHHAD syndrome, we performed WES for Case 1 and Case 2. Since ROHHAD syndrome in these individuals was sporadic and had childhood onset, we assumed the following inheritance patterns: (1) biallelic variants in recessive genes and (2) hemizygous variants in X-chromosome genes in Case 1. Variant filtering reduced the number of candidate genes to five in Case 1 and three in Case 2, respectively, as outlined in Supplementary Table S3. In Case 1, variant filtering was begun with 188,415 variants from the normal reference sequence. This number was reduced to 1,914 upon exclusion of homozygous and hemizygous variants in healthy domestic individuals, common variants (minor allele frequencies >1% in public databases), and synonymous variants. Upon considering only those genes with hemizygous variants or more than two variants in the same gene, the number of variants was further reduced to 50 variants (14 genes). Exclusion of artefacts by direct inspection of sequence alignment and exclusion of variants with minor allele frequencies < 0.005 in public databases left six variants in three candidate genes—PIK3R3, SPTBN5, and PCF11 (Supplementary Table S4). These variants were predicted likelihood to be deleterious for the function of the encoded protein in some prediction tools and PIK3R3, SPTBN5, and PCF11 are not linked to any disease phenotype in human yet. The WES of Case 2 was analyzed in the same manner to identify candidate variants (Supplementary Table S4), but none of them overlapped with variants identified in Case 1; SRMS and ZNF4 were not linked to any disease phenotypes, whereas mutations in KMT2B, which encodes lysine-specific methyltransferase 2B, cause childhood-onset dystonia [56]. All variants were confirmed by Sanger sequencing of the DNA of the affected individuals.


Gene Location ProteinFunction Reference Number

RAI117p11.2p.R1089XCraniofacial and nervous system developmentThaker et al. [12]

NTRK29q21.33p.P204H
Tropomyosin receptor kinase B (TrkB),
Neuroendocrine /synaptic plasticityIze-Ludlow et al. [6]

NECDIN15q11–q13Necdin (p.V318A)Hypothalamic/respiratoryDe Pontual et al.[52]

ASCL112q23.2Human achaete-scute homolog 1 (hASH1)NeuroendocrineDe Pontual et al. [52]

PHOX2B4p13,Paired mesoderm homeobox protein 2B (NBPhox)Respiratory/autonomicIze-Ludlow et al. [6]
De Pontual et al. [52]

BDNF11p14.1Brain-derived neurotrophic factor (BDNF)Neuronal development/synaptic plasticityIze-Ludlow et al.[6]
Han et al. [53]

HCRT 17q21.2HypocretinsSleep/wake regulation, energy balance, and the control of breathingBarclay et al. [51]

HCRTR11p35.2Hypocretin receptor type 1 (HcrtR1),Sleep/wake regulation, energy balance, and the control of breathingBarclay et al. [51]

HCRTR26p12.1Hypocretin receptor type 2 (HcrtR2),Sleep/wake regulation, energy balance, and the control of breathingBarclay et al. [51]

HTR1A5q12.35-hydroxytryptamine (serotonin) receptor 1AAppetite control, energy regulation, autonomic response to homeostatic stressRand et al. [54]

OTP5q14.1Orthopedia (Otp) homeodomain proteinHypothalamic expression, with an important role in hypothalamic cell specification in the developing hypothalamusRand et al. [54]

ADCYAP118p11.32Adenylate Cyclase Activating Polypeptide 1Maintenance of normal energy homeostasis, respiratory chemosensitivity and preventing neonatal hypoventilation at reduced body temperaturesRand et al. [54]

In addition, we analyzed CNVs; has been previously abbreviated using WES in Case 1 and Case 2. The CNVs detected by both EXCAVATOR and ExomeDepth tools were 38 in Case 1 and 48 in Case 2, respectively. We specifically focused on deletion or duplication of alleles in an AR pattern; however, there was no surviving CNV upon manual inspection of WES data.

4. Discussion

ROHHAD/NET is a rare disease and differential diagnosis from other obesity syndromes or neuroendocrine disorders requires clinical suspicion based on its phenotype. The genetic basis of this syndrome is still unknown.

The first part of this study is a systematic review on phenotypes of ROHHAD/NET involving 46 studies with 158 patients. Clinical manifestation, laboratory findings, tumor characteristics, and patient courses were reviewed. The results showed that it has a pediatric onset and it is noteworthy that no adult case has been reported to date. There was a female preponderance, with the girls being twice as often affected than the boys, consistently in both IPD and APD. This finding is in contrast to what has been reported on acquired sleep disorders with a 2:1 predominance of males in the reported frequency of obstructive sleep apnea [57]. Rapid obesity may often be the first recognizable sign, since other endocrine dysfunctions are gradually present. The results implicated that common endocrine disorders such as hypothyroidism or precocious puberty may be early signs for recognition. In addition, it has been reported that one of the major effects of hypothyroidism is its influence on the central ventilatory control and that both hypoxic and hypercapnic ventilatory impairment are significantly present in untreated thyroid insufficiency [58]. Such impaired ventilatory responses are thought to be related to the decrease in oxygen consumption associated with hypothyroidism [59]. In that, it is tempting to speculate that disturbance of thyroid function may be in part responsible for respiratory distress in patients with ROHHADNET. Electrolyte imbalance, especially dysnatremia, was present in a majority of the patients, requiring attention. Impaired water balancing condition such as polydipsia or diabetes insipidus due to hypothalamic dysfunction may have caused dysnatremia. Ganglioneuromas were the most common type of accompanied tumor and may presented not only as abdominal but also as mediastinal masses. We therefore suggest that suspected patients take both thoracic and abdominal imaging to screen for tumors. As ROHHAD/NET involves progressive impairment of the respiratory center, we observed that artificial ventilation was commonly initiated from the first place. Cardiac arrest probably due to preceding respiratory arrest was the major cause of deaths in these patients. We noted that all of the patients were already exposed to hypoxemia at the time of diagnosis. We believe that earlier recognition and timely application of pressure supporting devices during sleep may improve the quality of life and prevent sudden death.

The second part of this study was a WES which attempted to identify the genetic basis of ROHHAD/NET. It has been noted that central hypoventilation syndrome (CHS) resulting from PHOX2B mutations is associated with tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma) in approximately 6% of cases [59]. However, the association of ROHHADNET and PHOX2B mutations has not been identified. Recently, several studies have made progress in investigating genetic basis of ROHHAD/NET (Table 7). Thaker et al.[12] identified a de novo retinoic acid-induced 1 (RAI1) gene mutation in a child with ROHHAD and proposed RAI1 as a candidate gene for children with morbid obesity. Furthermore, there were studies which performed NGS in a set of ROHHAD/NET patients [6, 51, 52, 54]. Rand and colleagues [54] analyzed 5-hydroxytryptamine receptor 1A (HTR1A), orthopedia (OTP), and Adenylate Cyclase Activating Polypeptide 1 (ADCYAP1, formerly PACAP) genes which are involved in the embryologic development of the hypothalamus and autonomic nervous system in a set of 25 ROHHAD patients and 25 matched controls. Although there were no significantly correlating variations, this report provided evidence that variation of the HTR1A, OTP, and ADCYAP1 genes are unlikely responsible for ROHHAD/NET. Barclay et al. [51] analyzed 16 ROHHAD patients using a combination of NGS and Sanger sequencing. They examined mutations in the exons of the genes for hypocretin and accompanying receptors, namely, HCRT, HCRTR1, and HCRTR2, and found no rare or novel mutations. In this study, we also identified rare variants in two ROHHAD/NET patients. However, the causality of these variants remains unclear and demands further investigation. Nevertheless, we believe that accumulation of these attempts would contribute to progress.

There are some limitations in our research. Firstly, we could not analyze the relationship between the treatments and the subsequent outcomes. Secondly, there remains the possibility of existing case reports or series that were not accessible. Thirdly, some studies only had grouped data where IPD were not available. Nevertheless, this study also has its strengths in that it provides a pooled data and combined evidence on a disease of extreme rarity.

ROHHAD/NET is a rare disease, which has pediatric onset and female preponderance. Rapid obesity and hypothalamic dysfunction are earliest detectable signs. Prompt recognition and timely application of respiratory support may prevent grave complications leading to unprepared mortality. WES on 2 ROHHADNET patients identified no significant mutations or copy number variations. Further analyses of patients in prospective studies are required.

Data Availability

The data used to support the findings of this study are included within the main manuscript and the supplementary information file.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Jiwon M. Lee, Jaewon Shin, and Sol Kim contributed equally to the work

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1D1A1A01056685 to Heon Yung Gee), and by Chungnam National University Hospital Research Fund (2017-CF-023 to Jiwon M. Lee).

Supplementary Materials

Supplementary Table : checklist summarizing compliance with PRISMA guidelines Supplementary Table : clinical details of the two patients included in WES. Supplementary Table : filtering process of whole exome sequencing analysis performed in two patients. Supplementary Table : possible variants identified in individuals with ROHHAD syndrome by WES. (Supplementary Materials)

References

  1. D. Reppucci, J. Hamilton, E. A. Yeh, S. Katz, S. Al-Saleh, and I. Narang, “ROHHAD syndrome and evolution of sleep disordered breathing,” Orphanet Journal of Rare Diseases, vol. 11, no. 1, article no. 106, 2016. View at: Publisher Site | Google Scholar
  2. ROHHADNET, National Organization for Rare disorders (NORD), http://rarediseases.org/rare-diseases/rapid-onset-obesity-with-hypothalamic-dysfunction-hypoventilation-and-autonomic-dysregulation/.
  3. A. Abaci, G. Catli, E. Bayram et al., “A case of rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor: Rohhadnet syndrome,” Endocrine Practice, vol. 19, no. 1, pp. e12–e16, 2013. View at: Publisher Site | Google Scholar
  4. B. Bagheri, E. Pourbakhtyaran, F. Talebi Kiasari, B. Taherkhanchi, S. Salarian, and A. Sadeghi, “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) syndrome: A case report,” Archives of Pediatric Infectious Diseases, vol. 5, no. 1, 2017. View at: Google Scholar
  5. D. Moher, A. Liberati, and J. Tetzlaff, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1006–1012, 2009. View at: Publisher Site | Google Scholar
  6. D. Ize-Ludlow, J. A. Gray, M. A. Sperling et al., “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood,” Pediatrics, vol. 120, no. 1, pp. e179–e188, 2007. View at: Publisher Site | Google Scholar
  7. Park J. S., J. H. Kim, and J. S. Lee, Rhabdomyolysis with acute renal failure and severe hypothermia in a 15-year-old obese boy Annual Meeting of Korea-Japan Society of Pediatric Nephrology, 2010.
  8. B. F. A. Uçar, Ö. Umur et al., “A case of rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation: ROHHAD syndrome,” Hormone Research in Paediatrics, vol. 80, 2013. View at: Google Scholar
  9. J. Jung, J. S. Lee, K. J. Cho et al., “Genetic Predisposition to Sporadic Congenital Hearing Loss in a Pediatric Population,” Scientific Reports, vol. 7, no. 1, 2017. View at: Publisher Site | Google Scholar
  10. A. Magi, L. Tattini, I. Cifola et al., “EXCAVATOR: detecting copy number variants from whole-exome sequencing data,” Genome Biology, vol. 14, no. 10, article R120, 2013. View at: Publisher Site | Google Scholar
  11. V. Plagnol, J. Curtis, M. Epstein et al., “A robust model for read count data in exome sequencing experiments and implications for copy number variant calling,” Bioinformatics, vol. 28, no. 21, pp. 2747–2754, 2012. View at: Publisher Site | Google Scholar
  12. V. V. Thaker, K. M. Esteves, M. C. Towne et al., “Whole exome sequencing identifies RAI1 mutation in a morbidly obese child diagnosed with ROHHAD syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 5, pp. 1723–1730, 2015. View at: Publisher Site | Google Scholar
  13. S. C. Gordon, T. RCM Stewart, A. S. Kenny et al., “The evolving phenotype in a patient with rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) and response to caffeine treatment,” American Journal of Respiratory and Critical Care Medicine, 2015. View at: Google Scholar
  14. V. T. P. V. Van Tellingen, “Obesity in rohhadnet syndrome: Does cortisol play a role?” Hormone Research in Paediatrics, vol. 84, 2015. View at: Google Scholar
  15. E. Grudnikoff, C. Foley, C. Poole, and E. Theodosiadis, “Nocturnal anxiety in a youth with rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (rohhad),” Indigo Journal, vol. 22, no. 3, pp. 235–237, 2013. View at: Google Scholar
  16. P. P. Patwari, C. M. Rand, E. M. Berry-Kravis, D. Ize-Ludlow, and D. E. Weese-Mayer, “Monozygotic twins discordant for ROHHAD phenotype,” Pediatrics, vol. 128, no. 3, pp. e711–e715, 2011. View at: Publisher Site | Google Scholar
  17. S. Sartori, E. Priante, A. Pettenazzo et al., “Intrathecal synthesis of oligoclonal bands in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome: New evidence supporting immunological pathogenesis,” Journal of Child Neurology, vol. 29, no. 3, pp. 421–425, 2014. View at: Publisher Site | Google Scholar
  18. K. Dhondt, P. Verloo, H. Verhelst, R. Van Coster, and S. Overeem, “Hypocretin-1 deficiency in a girl with ROHHAD syndrome,” Pediatrics, vol. 132, no. 3, pp. e788–e792, 2013. View at: Publisher Site | Google Scholar
  19. P. Bougnères, L. Pantalone, A. Linglart, A. Rothenbühler, and C. Le Stunff, “Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 3971–3980, 2008. View at: Publisher Site | Google Scholar
  20. I. Paz-Priel, D. W. Cooke, and A. R. Chen, “Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome,” Journal of Pediatrics, vol. 158, no. 2, pp. 337–339, 2011. View at: Publisher Site | Google Scholar
  21. A. Chandrakantan and T. J. Poulton, “Anesthetic considerations for rapid-onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysfunction (ROHHAD) syndrome in children,” Pediatric Anesthesia, vol. 23, no. 1, pp. 28–32, 2013. View at: Publisher Site | Google Scholar
  22. P. Kocaay, Z. Şıklar, E. Çamtosun, T. Kendirli, and M. Berberoğlu, “ROHHAD Syndrome: Reasons for Diagnostic Difficulties in Obesity,” Journal of Clinical Research in Pediatric Endocrinology, vol. 6, no. 4, pp. 254–257, 2014. View at: Publisher Site | Google Scholar
  23. S. P. Sumanasena, S. de Silva, I. Perera, A. Sudeen, and R. Wasala, “Rapid onset obesity, hypoventilation, hypothalamic, autonomic and thermal dysregulation, and neural tumour (ROHHADNET) syndrome presenting with Cushing syndrome.,” The Ceylon Medical Journal, vol. 57, no. 1, pp. 47-48, 2012. View at: Publisher Site | Google Scholar
  24. D. L. N. Atapattu and S. Arulmoli, “A case of rapid onset obesity, hypoventilation, hypothalamic dysregulation and neuroendocrine tumours-rohhadnet syndrome,” Hormone Research in Paediatrics, vol. 84, 2015. View at: Google Scholar
  25. K. Sethi, Y.-H. Lee, L. E. Daugherty et al., “ROHHADNET syndrome presenting as major behavioral changes in a 5-Year-old obese girl,” Pediatrics, vol. 134, no. 2, pp. e586–e589, 2014. View at: Publisher Site | Google Scholar
  26. N. F. A. Gallizia, I. Ceccherini et al., “Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation, and neural tumour (ROHHADNET) syndrome in two Italian patients: Clinical characterization and exome sequencing analysis,” Hormone Research in Paediatrics, vol. 78, 2012. View at: Google Scholar
  27. M. A. F. Baronio, D. Rinaldini, F. Baronio, A. Marsigli, D. Rinaldini et al., “Rapid onset obesity, endocrine hypertension and ganglioneuroblastoma intermixed: Early manifestation of ROHHAD-NET syndrome? Presentation of two cases,” Hormone Research in Paediatrics, vol. 80, 2013. View at: Google Scholar
  28. C. Chow, M. V. Fortier, L. Das et al., “Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome May Have a Hypothalamus-Periaqueductal Gray Localization,” Pediatric Neurology, vol. 52, no. 5, pp. 521–525, 2015. View at: Publisher Site | Google Scholar
  29. K. Kot, E. Moszczynska, A. Lecka-Ambroziak, M. Migdal, and M. Szalecki, “ROHHAD in a 9-year-old boy - Clinical case,” Endokrynologia Polska, vol. 67, no. 2, pp. 226–231, 2016. View at: Publisher Site | Google Scholar
  30. A. P. Cemeroglu, D. S. Eng, L. A. Most, C. M. Stalsonburg, and L. Kleis, “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome and celiac disease in a 13-year-old girl: Further evidence for autoimmunity?” Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 1, pp. 97–101, 2016. View at: Publisher Site | Google Scholar
  31. H. B. Chew, L. H. Ngu, and W. T. Keng, “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): A case with additional features and review of the literature,” BMJ Case Reports, 2011. View at: Publisher Site | Google Scholar
  32. M. L. Petty, “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) with intermittent cerebrospinal fluid histiocytosis,” Journal of Child Neurology, vol. 29, no. 10, 2014. View at: Google Scholar
  33. I. Maksoud and L. Kassab, “Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation syndrome,” Avicenna Journal of Medicine, vol. 5, no. 3, pp. 89–94, 2015. View at: Publisher Site | Google Scholar
  34. M. Sanklecha, S. Sundaresan, and V. Udani, “ROHHAD syndrome: The girl who forgets to breathe,” Indian Pediatrics, vol. 53, no. 4, pp. 343-344, 2016. View at: Publisher Site | Google Scholar
  35. H. Erensoy, M. E. Ceylan, and A. Evrensel, “Psychiatric Symptoms in Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome and its Treatment: A Case Report,” Chinese Medical Journal, vol. 129, no. 2, pp. 242-243, 2016. View at: Publisher Site | Google Scholar
  36. A. S. Al-Harbi, A. Al-Shamrani, and B. A. Al-Shawwa, “Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation in Saudi Arabia,” Saudi Medical Journal, vol. 37, no. 11, pp. 1258–1260, 2016. View at: Publisher Site | Google Scholar
  37. L. Aljabban, L. Kassab, N. A. Bakoura, M. F. Alsalka, and I. Maksoud, “Rapid-onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation and neuroendocrine tumor syndrome with a homogenous enlargement of the pituitary gland: a case report,” Journal of Medical Case Reports, vol. 10, no. 1, pp. 1–9, 2016. View at: Publisher Site | Google Scholar
  38. A Galewicz-zielinska, “P-FR. Treatment of obstructive sleep apnoea as one of thefeatures of the ultra-rare ROHHAD syndrome,” Journal of Sleep Research, vol. 21, p. 234, 2012. View at: Google Scholar
  39. L. A. Jacobson, S. Rane, L. J. McReynolds, D. A. Steppan, A. R. Chen, and I. Paz-Priel, “Improved behavior and neuropsychological function in children with ROHHAD after high-dose cyclophosphamide,” Pediatrics, vol. 138, no. 1, 2016. View at: Google Scholar
  40. A. Lucas-Herald, M. Davidson, P. Davies et al., “Two children with rapid onset obesity combined with respiratory and endocrine dysfunction. do they have ROHHAD?: Abstract G234(P) Table 1,” Archives of Disease in Childhood, vol. 97, no. Suppl 1, pp. A119.2–A119, 2012. View at: Publisher Site | Google Scholar
  41. S. Ibáñez-Micó, A. Marcos Oltra, S. de Murcia Lemauviel, R. Ruiz Pruneda, C. Martínez Ferrández, and R. Domingo Jiménez, “Síndrome ROHHAD (obesidad de rápida progresión, disfunción hipotalámica, hipoventilación y disregulación autonómica). Presentación de un caso y revisión de la literatura,” Neurología, vol. 32, no. 9, pp. 616–622, 2017. View at: Publisher Site | Google Scholar
  42. E. Esparza Isasa, M. Palomero Rodríguez, I. Acebedo Bambaren et al., “Anestesia en paciente pediátrico con síndrome de Rohhad,” Revista Española de Anestesiología y Reanimación, vol. 65, no. 9, pp. 525–529, 2018. View at: Publisher Site | Google Scholar
  43. Ü. G. Şiraz, D. Okdemir, G. Direk et al., “A Rare Cause of Hypothalamic Obesity, Rohhad Syndrome: 2 Cases,” Journal of Clinical Research in Pediatric Endocrinology, 2018. View at: Publisher Site | Google Scholar
  44. S. Gil and M. I. AM, “Clinical description of five pediatric patients with rapid-onset obesity and clinical signs suggestive of ROHHADNET syndrome,” Hor Res Paediatr, 2012. View at: Google Scholar
  45. H. J. D. Reppucci, A. Yeh, S. Al-Saleh, S. Katz, M. Witmans, and I. Narang, “Polysomnography findings in children with suspected rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD): A Canadian case series study,” Sleep, 2014. View at: Google Scholar
  46. R. Biancheri, F. Napoli, A. Calcagno et al., “O26 – 1915 Immunological studies in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) syndrome,” European Journal of Paediatric Neurology, vol. 17, pp. S8–S9, 2013. View at: Publisher Site | Google Scholar
  47. F. Napoli, R. Tallone, A. Calcagno et al., “Perypheral neuroblastic tumours and immunological studies in rohhadnet syndrome (rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation and neural tumour),” Hormone Research in Paediatrics, vol. 1, 84, no. 90, 2014. View at: Google Scholar
  48. S. F. Barclay, C. M. Rand, L. A. Borch et al., “Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): Exome sequencing of trios, monozygotic twins and tumours,” Orphanet Journal of Rare Diseases, vol. 10, no. 1, 2015. View at: Google Scholar
  49. I. Gueorguieva, A. Linglart, A. Rothenbuhler, C. Piquard, and P. Bougneres, “P111 - Le syndrome de ROHHADNET (Rapid-Onset Obesity Hypoventilation Hypothalamic Autonomic Dysregulation NEural Tumors), une obésité hypothalamique mal connue,” Archives de Pédiatrie, vol. 17, no. 6, p. 78, 2010. View at: Publisher Site | Google Scholar
  50. F. Abel, R. Lane, A. Laverty, and D. Kilner, “ROHHAD syndrome: an underdiagnosed condition?” Paediatric Respiratory Reviews, vol. 11, p. S101, 2010. View at: Publisher Site | Google Scholar
  51. S. F. Barclay, C. M. Rand, P. A. Gray et al., “Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD,” Respiratory Physiology & Neurobiology, vol. 221, pp. 59–63, 2016. View at: Publisher Site | Google Scholar
  52. L. De Pontual, D. Trochet, S. Caillat-Zucman et al., “Delineation of late onset hypoventilation associated with hypothalamic dysfunction syndrome,” Pediatric Research, vol. 64, no. 6, pp. 689–694, 2008. View at: Publisher Site | Google Scholar
  53. J. Han, “Rare Syndromes and Common Variants of the Brain-Derived Neurotrophic Factor Gene in Human Obesity,” in Genetics of Monogenic and Syndromic Obesity, vol. 140 of Progress in Molecular Biology and Translational Science, pp. 75–95, Elsevier, 2016. View at: Publisher Site | Google Scholar
  54. C. M. Rand, P. P. Patwari, E. A. Rodikova et al., “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: Analysis of hypothalamic and autonomic candidate genes,” Pediatric Research, vol. 70, no. 4, pp. 375–378, 2011. View at: Publisher Site | Google Scholar
  55. P. P. Patwari and L. F. Wolfe, “Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: Review and update,” Current Opinion in Pediatrics, vol. 26, no. 4, pp. 487–492, 2014. View at: Publisher Site | Google Scholar
  56. E. Meyer, K. J. Carss, J. Rankin, J. M. Nichols, D. Grozeva, A. P. Joseph et al., “Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia,” Nature Genetics, vol. 49, no. 2, pp. 223–237, 2017. View at: Publisher Site | Google Scholar
  57. F. Kapsimalis and M. H. Kryger, “Gender and obstructive sleep apnea syndrome, part 2: Mechanisms,” SLEEP, vol. 25, no. 5, pp. 499–506, 2002. View at: Google Scholar
  58. C. E. Milla and J. Zirbes, “Pulmonary complications of endocrine and metabolic disorders,” Paediatric Respiratory Reviews, vol. 13, no. 1, pp. 23–28, 2012. View at: Publisher Site | Google Scholar
  59. E. M. Berry-Kravis, L. Zhou, C. M. Rand, and D. E. Weese-Mayer, “Congenital central hypoventilation syndrome PHOX2B mutations and phenotype,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 10, pp. 1139–1144, 2006. View at: Publisher Site | Google Scholar

Copyright © 2018 Jiwon M. Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1442 Views | 407 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder